Overview

Ruxolitinib Combined With Dexamethasone for HLH

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Capital Research Institute of Pediatrics
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate